comparing the risks and benefits of adjunctive
play

Comparing the Risks and Benefits of Adjunctive Medications for PTSD Presenter Name Beth Cohen, MD MAS San Francisco VA Health Care System & University of California, San Francisco September 19, 2019 Beth Cohen Has nothing to disclose.

0 downloads 5 Views 1,14 MB Size Report
  1. Comparing the Risks and Benefits of Adjunctive Medications for PTSD Presenter Name Beth Cohen, MD MAS San Francisco VA Health Care System & University of California, San Francisco September 19, 2019

  2. Beth Cohen • Has nothing to disclose. 2

  3. Challenges in Pharmacologic Treatment of PTSD • In RCTs of first-line serotonin reuptake inhibitor (SRI) therapy: - 40% of patients do not have clinically significant improvements in PTSD symptoms - 70% do not achieve remission • Little evidence on what to do next 3

  4. Our Initial Research Goal • Many patients are prescribed antipsychotic medications - mixed evidence in trials - only 1 trial specifically in patients already on SRIs - many concerning metabolic side effects To determine the risks and benefits of adding antipsychotics to an SRI in patients with PTSD? 4

  5. Feedback from Partners • Patient partners: - many different types of medications used - “you feel like a guinea pig” - wanted information to participate in shared decision making • Stakeholder partners: - providers want to “do something” - no studies compare strategies, so there is no guidance 5

  6. Our Updated Research Goal • To compare the risks and benefits of several medications that are commonly added to SRIs: - antipsychotics - mirtazapine - tricyclic antidepressants - prazosin 6

  7. Methods • National VA electronic records 2007-2015 • PTSD but no bipolar/psychotic disorder • SRI ≥ 30 days • Augmenting medication added for ≥60 days: - Antipsychotics (N=70,900) - Mirtazapine (N=54,672) - Tricyclics (N=21,984) - Prazosin (N=100,269) • Compare outcomes in 1 year before vs. after addition of augmenting medication 7

  8. Methods: Outcomes • Benefits: - PTSD symptoms (PTSD Checklist) - Mental health ER visits and hospitalizations - Suicidality 8

  9. Methods: Outcomes • Risks: - Weight - Blood pressure - Labs: cholesterol, glucose, hemoglobin A1c - Cardiovascular disease events 9

  10. Results: PTSD Symptoms - On average, each group had very small improvements after addition of augmenting med - Similar by medication class 10

  11. Results: PTSD Symptoms - PTSD symptoms gradually increase and peak around time Rx is added - In 3-4 months, symptoms return to baseline levels 11

  12. Mental Health Emergency Room Visits - Augmenting med groups have different baseline mental health ER visit rates but % improvement is similar - In contrast to PTSD symptoms, there were more substantial average reductions ER visits 12

  13. Suicidal Thoughts - Small but clinically meaningful reductions in suicidal thoughts - Biggest improvements with prazosin and antipsychotics 13

  14. Weight - Most weight gain with antipsychotics/mirtazapine and no return to baseline 14

  15. Hemoglobin A1c - Greatest increase with mirtazapine and tricyclics 15

  16. Other Metabolic Outcomes • Triglycerides: increased 3-8% except for prazosin • No significant increases in blood pressure or cholesterol, but: - 20-30% increased/started medications to treat • Increase in diagnoses of cardiovascular disease events 16

  17. Summary • 2 nd line medications may be useful when PTSD symptoms worsen • Benefits similar across classes • Use associated with weight gain and other metabolic risks: mirtazapine>antipsychotics>tricyclics>prazosin 17

  18. Next Steps • Presenting locally and nationally • Working with stakeholder partners- NCPTSD, VA Office of Mental Health Operations • Compare to a “control” group with inadequate SRI response • Identify which patients are most likely to benefit 18

  19. Thank You • Project Team: Nancy Bernardy, Shira Maguen, Thomas Neylan, Annie Ryder, Karen Seal, Janet Tang, Ana-Marie Urbieta, Ilse Weichers, Anne Woods, Dmitri Young • VA Measurement Science QUERI: Mary Whooley, Craig Meyer, Niru Krishnamurthi, David Schopfer, Hui Shen, Katherine Williams, Ning Zhang • Funding: PCORI 19

  20. Learn More • www.pcori.org • info@pcori.org • #PCORI2019 20

  21. Questions? 21

  22. Thank You! Beth Cohen Comparing the Risks and Benefits of Adjunctive Medications for PTSD September 19, 2019 22

Recommend Documents


adjunctive therapies to neonatal ventilation
Adjunctive Therapies to Neonatal

Adjunctive Therapies to Neonatal Ventilation Sunil Sinha Professor of

immunotherapy case studies
Immunotherapy Case Studies Weighing

Immunotherapy Case Studies Weighing risks and benefits when risks are

benefits of biodiversity protection comparing in person
Benefits of biodiversity protection:

www.nina.no Cooperation and expertise for a sustainable future Benefits of

global risks global risks global risks global risks
GLOBAL RISKS GLOBAL RISKS GLOBAL

GLOBAL RISKS GLOBAL RISKS GLOBAL RISKS - GLOBAL RISKS - - - GLOBAL RISKS

wireless network security
Wireless Network Security Vedavyas

Wireless Network Security Vedavyas Duggirala CS 6204, Spring 2005 1

arbeitnehmerschutz und gesundheit am bau in der brd
Arbeitnehmerschutz und Gesundheit am

Arbeitnehmerschutz und Gesundheit am Bau in der BRD ( Germany - Analyzing and

risks benefits and filters
Risks, Benefits and Filters Beatrice

Children on Social Media: Risks, Benefits and Filters Beatrice Hayes Dr Dawn

committee on the risks and
Committee on the Risks and Benefits of

Presentation to the Select Committee on the Risks and Benefits of Hydraulic

lecture 1 chapter 1 benefits risks of statistics
Lecture 1/Chapter 1 Benefits &

Lecture 1/Chapter 1 Benefits & Risks of Statistics Organization of

how to find filter and format evidence based information
How to find, filter, and format

How to find, filter, and format Evidence-based Information on the Benefits

atypical antipsychotics in
Atypical Antipsychotics in Phizer

6/13/2018 Disclosures Current clinical trial funded by Auspex/Teva Past

latuda commercial update
LATUDA Commercial Update LATUDA

LATUDA Commercial Update LATUDA Meeting (Tokyo) January 2011 Mark Iwicki

sa fe ly re duc ing the use o f antipsyc ho tic me dic a
Sa fe ly Re duc ing the Use o f

Sa fe ly Re duc ing the Use o f Antipsyc ho tic Me dic a tio ns An Ove

cea
CEA Works Well! Large Amounts of

QUESTIONS Is carotid artery stenting (CAS) FEASABLE ? Carotid Endarterectomy

anticoagulatie en de oudere pati nt terughoudenheid
Anticoagulatie en de oudere patint:

Anticoagulatie en de oudere patint: Terughoudenheid gerechtvaardigd of niet?

what goes together peanut butter amp jam cookies amp milk
What Goes Together: Peanut Butter

What Goes Together: Peanut Butter & Jam, Cookies & Milk Antiplatelets

ri antipsychotic med reduction challenges to the qin qio
RI Antipsychotic Med Reduction

RI Antipsychotic Med Reduction Challenges to the QIN-QIO 11 th Statement of

psychotropics and foster care challenge or opportunity
Psychotropics and Foster Care:

Psychotropics and Foster Care: Challenge or Opportunity? Raymond C. Love,

care talks
CARE TALKS Sustaining Practice Now

CARE TALKS Sustaining Practice Now That The Project Is Officially Over More

working to eliminate inappropriate antipsychotic
Working to Eliminate Inappropriate

Working to Eliminate Inappropriate Antipsychotic Medication Use

psychosis an illness of young improving conditions for
Psychosis: an illness of young

20112015 Psychosis: an illness of young Improving conditions for recovery:

quality of care in medi cal
Quality of Care in Medi-Cal:

Quality of Care in Medi-Cal: Understanding HEDIS for Children in Foster Care